Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Caitlin Meservey"'
Autor:
Kalliopi P. Siziopikou, Jacqueline S. Jeruss, Sara Barnato Giordano, WL Gradishar, Steve Rosen, Kevin P. Bethke, Virginia G. Kaklamani, J H Von Roenn, Nora M. Hansen, Seema A. Khan, Caitlin Meservey
Publikováno v:
Cancer Research. 73:P3-14
Background: Several neoadjuvant trials have been conducted directed at treating triple negative breast cancer (TNBC) patients with platinum agents with pathologic complete response (pCR) rates ranging from 16%-32%. Eribulin mesylate, a nontaxane micr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61025c54b63e739a2b6a35361ef238d5
https://doi.org/10.1158/0008-5472.sabcs13-p3-14-14
https://doi.org/10.1158/0008-5472.sabcs13-p3-14-14
Autor:
Krystal Brown, Sara Barnato Giordano, Kent Hoskins, Kirsten Timms, Cara Solimeno, Seema A. Khan, Kevin P. Bethke, William J. Gradishar, Alexander Gutin, Vamsi Parini, Irene Helenowski, Joshua Jones, Jacqueline S. Jeruss, Anne Renee Hartman, Steven T. Rosen, Borko Jovanovic, Victor Abkevich, Kalliopi P. Siziopikou, Regina Uthe, Virginia G. Kaklamani, Elisha Hughes, Sarika Jain, Jamie H. Von Roenn, Nora M. Hansen, Caitlin Meservey, Zaina Sangale
Publikováno v:
Breast cancer research and treatment. 151(3)
The purpose of this study is to evaluate the efficacy and safety of neoadjuvant treatment with carboplatin and eribulin in patients with early-stage triple negative breast cancer (TNBC), and to explore biomarkers based on DNA and protein expression p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef7f336b7e7a5e196a1df6a532790275
https://pubmed.ncbi.nlm.nih.gov/26006067
https://pubmed.ncbi.nlm.nih.gov/26006067
Autor:
Jacqueline S. Jeruss, William J. Gradishar, Virginia G. Kaklamani, Jeffrey D. Wayne, Kevin P. Bethke, Jamie H. Von Roenn, Seema A. Khan, Jennifer Gordon, Steven T. Rosen, Regina Uthe, Mary Cianfrocca, Mario E. Lacouture, Vamsi Parimi, Denise M. Scholtens, Borko Jovanovic, Nora M. Hansen, Caitlin Meservey, Kalliopi P. Siziopikou
Publikováno v:
Breast cancer research and treatment. 132(3)
Lapatinib, a dual kinase inhibitor against epidermal growth factor receptor (EGFR) and human epidermal receptor two (HER2) has shown efficacy in treating HER2 positive breast cancer. Nanoparticle albumin bound (nab) paclitaxel was developed to reduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::953691a32f2b669d46f489a80741dca4
https://pubmed.ncbi.nlm.nih.gov/21359953
https://pubmed.ncbi.nlm.nih.gov/21359953
Autor:
Anne-Renee Hartman, Nora M. Hansen, Caitlin Meservey, Steven T. Rosen, Victor Abkevich, Jacqueline S. Jeruss, Cara Solimeno, Kalliopi P. Siziopikou, Irene Helenowski, Regina Uthe, Virginia G. Kaklamani, Elisha Hughes, Sarika Jain, William J. Gradishar, Seema Kahn, Jamie H. Von Roenn, Kent Hoskins, Kevin P. Bethke, Kirsten Timms, Borko Jovanovic
Publikováno v:
Journal of Clinical Oncology. 33:1017-1017
1017 Background: Platinum-based chemotherapy has been reported to have efficacy in patients with Triple Negative Breast Cancer (TNBC). Germline BRCA1/2 mutation status has been shown to be predicti...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed0463758ee8fa795008643afa9f08cb
https://doi.org/10.1200/jco.2015.33.15_suppl.1017
https://doi.org/10.1200/jco.2015.33.15_suppl.1017
Autor:
Jamie H. Von Roenn, Jacqueline S. Jeruss, Kalliopi P. Siziopikou, Shreyas S. Rao, Virginia G. Kaklamani, R Hamdan, Kevin P. Bethke, Steven T. Rosen, William J. Gradishar, Sara Barnato Giordano, Nora M. Hansen, Caitlin Meservey, Seema A. Khan
Publikováno v:
Molecular Cancer Research. 11:A065-A065
Background: Several neoadjuvant trials have been conducted directed at treating triple negative breast cancer (TNBC) patients with platinum agents with pathologic complete response (pCR) rates ranging from 16%-32%. Eribulin mesylate, a nontaxane micr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31a9ba2b10a3eca3f993fcaa4de08895
https://doi.org/10.1158/1557-3125.advbc-a065
https://doi.org/10.1158/1557-3125.advbc-a065
Autor:
Deborah A. Smith, Mary Cianfrocca, Virginia G. Kaklamani, Caitlin Meservey, Jamie H. Von Roenn, Regina Uthe, Alfred Rademaker, Steven T. Rosen, Stephen D. Rubin, William J. Gradishar
Publikováno v:
Journal of Clinical Oncology. 30:610-610
610 Background: Liposomal formulations including pegylated liposomal doxorubicin (PLD) were developed to improve the therapeutic index of anthracyclines (A). Lapatinib (L) is a selective, highly competitive inhibitor of ErbB1 and ErbB2 tyrosine kinas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db67ebbf190464f6125a918cabd599e4
https://doi.org/10.1200/jco.2012.30.15_suppl.610
https://doi.org/10.1200/jco.2012.30.15_suppl.610
Autor:
Jamie H. Von Roenn, Nora M. Hansen, Steven T. Rosen, Caitlin Meservey, Sara E. Barnato, Virginia G. Kaklamani, Seema A. Khan, Kalliopi P. Siziopikou, Jacqueline Sara Jeruss, William J. Gradishar, Kevin P. Bethke
Publikováno v:
Journal of Clinical Oncology. 30:TPS1134-TPS1134
TPS1134 Background: Several neoadjuvant trials have been conducted in triple negative breast cancer (TNBC) with platinum agents with pathologic complete response (pCR) ranging from 16%-32%. Eribulin mesylate, a nontaxane microtubule dynamics inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f317b72b1b073e77038b5a563f81353d
https://doi.org/10.1200/jco.2012.30.15_suppl.tps1134
https://doi.org/10.1200/jco.2012.30.15_suppl.tps1134